In this segment from Market Checkup, Motley Fool health-care analysts David Williamson and Michael Douglass dive into Novartis' (NYSE:NVS) recent earnings report, to give investors the key takeaways from the company this quarter.

The guys discuss how earnings were largely in line with expectations and note how the company's recent deal to acquire GlaxoSmithKline's (NYSE:GSK) early-stage oncology business while divesting itself of its vaccines business has made Novartis a more focused company. While David isn't terribly excited about the stock at the moment, the addition of this business to Novartis' own early stage oncology assets means that David does see the potential for outperformance here in the long run, for investors who are willing to wait.

6 stock picks poised for incredible growth
They said it couldn't be done. But David Gardner has proved them wrong time, and time, and time again with stock returns like 926%, 2,239%, and 4,371%. In fact, just recently one of his favorite stocks became a 100-bagger. And he's ready to do it again. You can uncover his scientific approach to crushing the market and his carefully chosen six picks for ultimate growth instantly, because he's making this premium report free for you today. Click here now for access.

David Williamson owns shares of Novartis. Michael Douglass and The Motley Fool have no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.